Page last updated: 2024-11-01

ondansetron and Hypocalcemia

ondansetron has been researched along with Hypocalcemia in 1 studies

Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Hypocalcemia: Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gallegos-Castorena, S1
Martínez-Avalos, A1
Mohar-Betancourt, A1
Guerrero-Avendaño, G1
Zapata-Tarrés, M1
Medina-Sansón, A1

Trials

1 trial available for ondansetron and Hypocalcemia

ArticleYear
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
    Pediatric hematology and oncology, 2007, Volume: 24, Issue:6

    Topics: Adolescent; Amifostine; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms;

2007